The emergence of Retatrutide ZPHC, at a concentration of 120mg, is sparking considerable excitement within the healthcare community. This novel dual GIP and GLP-1 receptor medication appears to provide notable improvements in fat reduction compared to existing therapies. Preliminary patient trial